By Dave Sebastian

 

Regeneron Pharmaceuticals Inc. said its independent data monitoring committee for its Covid-19 antibody cocktail recommended that the company pause the enrollment of patients requiring high-flow oxygen or mechanical ventilation.

The committee made the decision based on a potential safety concern and unfavorable risk-benefit profile, Regeneron said Friday.

Regeneron said the committee still recommends the continued enrollment of hospitalized patients who require no or low-flow oxygen and outpatient trial without modification.

 

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

October 30, 2020 11:16 ET (15:16 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Regeneron Pharmaceuticals Charts.